A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine

Marco Bartolini, Maria Adele Giamberardino, Carlo Lisotto, Paolo Martelletti, Davide Moscato, Biagio Panascia, Lidia Savi, Luigi Alberto Pini, Grazia Sances, Patrizia Santoro, Giorgio Zanchin, Stefano Omboni, Michel D. Ferrari, Filippo Brighina, Brigida Fierro

Research output: Contribution to journalArticlepeer-review

Abstract

The objective of this study was to evaluate patients' satisfaction with acute treatment of migraine with frovatriptan or almotriptan by preference questionnaire. One hundred and thirty three subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or almotriptan 12.5 mg, treating 1-3 attacks. The study had a multicenter, randomized, double blind, cross-over design, with treatment periods lasting

Original languageEnglish
Pages (from-to)361-368
Number of pages8
JournalJournal of Headache and Pain
Volume12
Issue number3
DOIs
Publication statusPublished - Jun 2011

Keywords

  • Almotriptan
  • Frovatriptan
  • Migraine
  • Patient preference

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology

Fingerprint Dive into the research topics of 'A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine'. Together they form a unique fingerprint.

Cite this